Free Trial

Precision BioSciences (DTIL) Projected to Post Earnings on Thursday

Precision BioSciences logo with Medical background

Precision BioSciences (NASDAQ:DTIL - Get Free Report) is expected to release its Q1 2025 earnings data before the market opens on Thursday, May 15th. Analysts expect the company to announce earnings of ($0.38) per share and revenue of $5.00 million for the quarter.

Precision BioSciences (NASDAQ:DTIL - Get Free Report) last issued its earnings results on Wednesday, March 26th. The company reported ($3.20) EPS for the quarter, missing analysts' consensus estimates of ($2.09) by ($1.11). The company had revenue of $3.47 million during the quarter, compared to analysts' expectations of $4.28 million. Precision BioSciences had a negative return on equity of 23.69% and a net margin of 11.48%. On average, analysts expect Precision BioSciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Precision BioSciences Stock Performance

DTIL stock traded up $0.01 during trading on Friday, hitting $5.16. 96,089 shares of the company traded hands, compared to its average volume of 182,599. Precision BioSciences has a 1 year low of $3.61 and a 1 year high of $13.44. The company has a market cap of $54.44 million, a PE ratio of 86.01 and a beta of 1.55. The stock's 50-day simple moving average is $5.03 and its 200 day simple moving average is $5.61. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. HC Wainwright reiterated a "buy" rating and issued a $60.00 target price on shares of Precision BioSciences in a research note on Friday, March 28th. BMO Capital Markets upgraded Precision BioSciences from a "market perform" rating to an "outperform" rating and set a $34.00 price objective for the company in a research report on Friday, January 10th.

Read Our Latest Report on DTIL

About Precision BioSciences

(Get Free Report)

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.

Read More

Earnings History for Precision BioSciences (NASDAQ:DTIL)

Should You Invest $1,000 in Precision BioSciences Right Now?

Before you consider Precision BioSciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precision BioSciences wasn't on the list.

While Precision BioSciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines